We are live on ! Find out more

AtriCure

ATRC

Market cap $2.84B

55.81 USD

+2.97

5.62%

At close Updated Oct 9, 4:00 PM EDT

Pre-market

After hours

55.81

0.00

0%

1 day

5.62%

5 days

3.08%

1 month

5.24%

3 months

61.49%

6 months

98.97%

Year to date

42.12%

1 year

53.03%

5 years

-20.63%

10 years

221.12%

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Employees: 1,350

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 37.5%

Neutral 50%

Negative 12.5%

Zacks Investment Research

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

The Motley Fool

AtriCure CTO Sells 3,657 Shares

The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.

AtriCure CTO Sells 3,657 Shares

Zacks Investment Research

Do Options Traders Know Something About AtriCure Stock We Don't?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Do Options Traders Know Something About AtriCure Stock We Don't?

Zacks Investment Research

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

The Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The Motley Fool

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

See News Rankings

Price charts implemented using Lightweight Charts™